Xilio Therapeutics, Inc. has announced a 1-for-14 reverse stock split effective March 13, 2026, aimed at increasing its stock price to meet Nasdaq's minimum bid requirement. This move follows stockholder approval at a special meeting on February 23, 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.